In this article, we are going to look at which company has outperformed in Indian pharma in October 2023. Recently, a name of a company has come out regarding the pharma company which has outperformed the Indian pharma market growth in the last month. The Indian Pharma Market (IPM) growth has picked up the pace in the last month at 16.5 Year on year which is led by the rebound in the Acute segment growth and low base of the last year. Now in this article, we are going to learn everything about the pharma company that has outperformed in October 2023 in the Indian pharma. So read this article till the end.
In October 2023, the Indian Pharma market (IPM) has picked up a good growth which is led by the Acute segment growth and low base of the last year. According to Motilal Oswal Financial Services Ltd, the Indian pharma market has taken a hump of 16.5% Year on year in the last month versus 3.3% in the same month last year. and 8.6% in Sepetember 2023. The Acute growth has now finally recovered to 18% YoY growth in the last month whereas on the other hand, chronic growth has stood at 14% YoY. This has been officially claimed by the Kotak Institutational Equities.
There was a bulk growth of the IPM growth in the last month as it was driven by therapies like anti-malarial, anti-infectives, gastro-intestinal therapies, and immunomodulators. The pickup in the growth rate has been recorded after the deterioration for some previous months which was encouraging and also listing the entire growth of IPM. As per the source, the company that outperformed in October 2023 is IPCA Laboratories Limited, IPCA growth stood up at 24% YoY in the last month. IPCA has a great range of products in the acute segment and anti-malarial drugs rebound in the acute segment and also picked in the Anti Infective and Anit-Malarial sales which helped in the growth of the catch pace domestically.
The domestic sales of IPCA at the time of the September 2023 quarter have grown up which has helped by the Pain management therapy which is growing to 12% as it is followed by great growth in cardiac. Reports have shown that the pick up in the sales of these products is now going to improve the prospects of IPCA in the current quarter. More details are to be shared very soon, so stay tuned with us.